Greenstone Biosciences, Inc.

Greenstone Biosciences, Inc., a for-profit biotechnology company based in Palo Alto, California, performs federal grant-funded research in small-molecule drug discovery and cell-based drug screening platforms for rare cardiovascular and muscular diseases, operating as a research grant recipient (83% of recent awards) and as a subcontractor on federal contracts. The vendor holds no federal prime contract awards; all work flows through either direct federal research grants or subcontracts under prime contractors.

Greenstone's federal footprint concentrates in National Institutes of Health research programs. The National Heart, Lung, and Blood Institute funds two of six total awards; the Defense Health Agency funds two additional awards; and the National Center for Advancing Translational Sciences funds one. A sixth award sits on a NASA Johnson Space Center GWAC. Combined obligated dollars across all awards total $6.4 million. The most recent award, dated August 1, 2026, is a $625,968 grant from NHLBI under the Cardiovascular Diseases Research program (CFDA 93.837) for small-molecule drug discovery targeting cardiac fibrosis in Duchenne muscular dystrophy using artificial intelligence, machine learning, and induced pluripotent stem cell-derived organoids. The work splits between an R61 phase performing unbiased proteomics, computational screening of 30 billion candidate molecules via generative AI and molecular docking, and bioactive compound library screening on DMD iPSCs, followed by an R33 phase synthesizing and validating lead compounds through May 31, 2028. Earlier representative work includes a June 2024 NCATS grant for myotonic dystrophy drug discovery combining iPSC technology with AI/ML, a May 2024 Defense Health Agency grant for elucidating mechanistic pathways in LMNA cardiomyopathy, and a September 2023 NHLBI Small Business Innovation Research (SBIR) grant developing an ethnically diverse iPSC-cardiomyocyte panel for pharmacogenomics and drug-safety testing across 100 unique donor lines. On the subcontract side, Greenstone subcontracts to KBR Wyle Services, LLC on a November 2025 award for human induced pluripotent stem cells work under the HHPC2 program. Activity is recent and episodic — one award in 2023, three in 2024, one in 2025, and one in 2026 — with two awards (combined potential value not specified in source) facing ultimate completion within the next twenty-four months. Greenstone's capability portfolio centers on iPSC technology, computational drug discovery platforms, and cardiotoxicity screening models for pharmaceutical development and rare-disease therapeutic applications.